Abound Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Abound Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246	Hold	2	–	–	﹤0.01%	1072
2026 Q1	$211	Sell	2 -2	-50%	-$177	﹤0.01%	1224
2025 Q4	$350	Hold	4	–	–	﹤0.01%	1008
2025 Q3	$266	Hold	4	–	–	﹤0.01%	1039
2025 Q2	$222	Hold	4	–	–	﹤0.01%	1003
2025 Q1	$194	Hold	4	–	–	﹤0.01%	995
2024 Q4	$155	Sell	4 -1	-20%	-$44	﹤0.01%	1165
2024 Q3	$225	Buy	+5	New	+$202	﹤0.01%	1094

Other funds holding PTGX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Cache Advisors San Francisco, California $1.18B AUM 44.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Abound Wealth Management's PTGX Position: Q2 2026 in Review

Abound Wealth Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 2 shares worth $246. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

Abound Wealth Management first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $350 in Q4 2025. 25 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Abound Wealth Management held 2 shares of Protagonist Therapeutics worth $246 as of Q2 2026.
Abound Wealth Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1072 holding.
Abound Wealth Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
Abound Wealth Management's Protagonist Therapeutics position peaked at $350 in Q4 2025.
25 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.